Issue 5/2008
Content (10 Articles)
Plasma and tissue disposition of non-liposomal DB-67 and liposomal DB-67 in C.B-17 SCID mice
William C. Zamboni, Laura L. Jung, Sandra Strychor, Erin Joseph, Beth A. Zamboni, Sarah A. Fetterman, Brian J. Sidone, Thomas G. Burke, Dennis P. Curran, Julie L. Eiseman
Synergy of Irofulven in combination with various anti-metabolites, enzyme inhibitors, and miscellaneous agents in MV522 lung carcinoma cells: marked interaction with gemcitabine and 5-fluorouracil
Michael J. Kelner, Trevor C. McMorris, Rafael J. Rojas, Leita A. Estes, Pharnuk Suthipinijtham
Inhibitory effects of quercetin derivatives on phosphodiesterase isozymes and high-affinity [3 H]-rolipram binding in guinea pig tissues
Agnes L.-F. Chan, Hui-Lin Huang, Hui-Chi Chien, Chi-Ming Chen, Chun-Nan Lin, Wun-Chang Ko
Growth inhibition and induction of apoptosis in MCF-7 breast cancer cells by a new series of substituted-1,3,4-oxadiazole derivatives
Akhilesh Kumar, Saritha S. D’Souza, S. L. Gaonkar, K. M. L. Rai, Bharathi P. Salimath
Synthesis and in vitro antiproliferative activity against human cancer cell lines of novel 5-(4-methyl-benzylidene)-thiazolidine-2,4-diones
S. Chandrappa, S. B. Benaka Prasad, K. Vinaya, C. S. Ananda Kumar, N. R. Thimmegowda, K. S. Rangappa
Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors
Michael J. Overman, Gauri Varadhachary, Scott Kopetz, Melanie B. Thomas, Masakazu Fukushima, Keizo Kuwata, Akira Mita, Robert A. Wolff, Paulo M. Hoff, Henry Xiong, James L. Abbruzzese
Effect of coadministration of ketoconazole, a strong CYP3A4 inhibitor, on pharmacokinetics and tolerability of motesanib diphosphate (AMG 706) in patients with advanced solid tumors
Patricia LoRusso, Elisabeth I. Heath, Jesse McGreivy, Yu-Nien Sun, Rebeca Melara, Lucy Yan, Lisa Malburg, Megan Ingram, Jeffrey Wiezorek, Li Chen, Mary Jo Pilat
A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?
Andrew H. Ko, Elizabeth Dito, Brian Schillinger, Alan P. Venook, Zhidong Xu, Emily K. Bergsland, Derrick Wong, Janet Scott, Jimmy Hwang, Margaret A. Tempero
Favorable survival observed after carboplatin, paclitaxel, and concurrent accelerated hyperfractionated radiotherapy for treatment of locally advanced head and neck carcinoma
Dennis L. Carter, Lina Asmar, David Barrera, John Caracandas, J. Shaker Dakhil, Dean McCracken, Mark A. O’Rourke, Richard K. Rosenberg, Kristi A. Boehm, Des Ilegbodu, Robert L. Reid
Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer
Johan Vansteenkiste, Eric Van Cutsem, Herlinde Dumez, Cong Chen, Justin L. Ricker, Sophia S. Randolph, Patrick Schöffski